Interleukin (IL)-2 is a pleiotropic cytokine that is necessary to prevent chronic inflammation in the gastrointestinal tract 1-4 . The protective effects of IL-2 involve the generation, maintenance and function of regulatory T (T reg ) cells [4] [5] [6] [7] [8] , and the use of low doses of IL-2 has emerged as a potential therapeutic strategy for patients with inflammatory bowel disease 9 . However, the cellular and molecular pathways that control the production of IL-2 in the context of intestinal health are undefined. Here we show, in a mouse model, that IL-2 is acutely required to maintain T reg cells and immunological homeostasis throughout the gastrointestinal tract. Notably, lineage-specific deletion of IL-2 in T cells did not reduce T reg cells in the small intestine. Unbiased analyses revealed that, in the small intestine, group-3 innate lymphoid cells (ILC3s) are the dominant cellular source of IL-2, which is induced selectively by IL-1β. Macrophages in the small intestine produce IL-1β, and activation of this pathway involves MYD88-and NOD2-dependent sensing of the microbiota. Our loss-of-function studies show that ILC3-derived IL-2 is essential for maintaining T reg cells, immunological homeostasis and oral tolerance to dietary antigens in the small intestine. Furthermore, production of IL-2 by ILC3s was significantly reduced in the small intestine of patients with Crohn's disease, and this correlated with lower frequencies of T reg cells. Our results reveal a previously unappreciated pathway in which a microbiota-and IL-1β-dependent axis promotes the production of IL-2 by ILC3s to orchestrate immune regulation in the intestine.
Il2
f/f mice exhibited a complete loss of IL-2 protein staining in T cells, and we observed a significant reduction in the number of T reg cells, and an increase in CD4 + T cell proliferation and effector function in the mesenteric lymph nodes and large intestine (Extended Data Fig. 2a-g ). By contrast, deletion of T-cell-derived IL-2 did not alter T reg cells, CD4 + T cell proliferation or effector cytokine production within the small intestine (Extended Data Fig. 2h-k) . Collectively, these data demonstrate that T-cell-derived IL-2 is required for maintaining immunological homeostasis in lymphoid tissues and the large intestine but is dispensable in the small intestine, which indicates the existence of other critical cellular sources of IL-2.
We next examined the relevant cellular sources of IL-2 in the healthy mammalian small intestine by unbiased flow cytometry analyses. Notably, we observed that the major population of IL-2 + cells lack lineage markers for T cells, B cells, macrophages and dendritic cells, but are CD127 + , CD90.2 + and express retinoic-acid-related orphan receptor γt (RORγt) (Fig. 1a) , which represents a phenotype that is consistent with ILC3s [11] [12] [13] . To directly compare Il2 transcript levels between CD4
+ T cells and ILC3s in the healthy small intestine, we performed RNA sequencing on sorted cell populations. In comparison to differentially expressed genes found in ILC3s (Rorc, Il22, Il1r (also known as Il1r1) and Il23r) or CD4 + T cells (Cd3d), expression of Il2 was more highly enriched in ILC3s (Fig. 1b) . Significantly higher expression of Il2 was confirmed in ILC3s relative to CD4 + T cells, dendritic cells or B cells after quantitative PCR analysis of populations that were purified from the healthy mouse small intestine (Fig. 1c ). ILC3s were the most-abundant IL-2 + cell type in terms of frequency and total cell number among other subsets of innate lymphoid cells and total CD4 + T cells from the small intestine ( Fig. 1d-f , Extended Data Fig. 3 ), and were present at higher cell numbers than effector and memory CD4 + T cells (Extended Data Fig. 4a ). This is in contrast to the large intestine, in which the majority of IL-2 was produced by CD4 + T cells and there was a limited presence of innate lymphoid cells that produce IL-2 (Extended Data Fig. 4b-d ). ILC3s are a heterogeneous population that includes both CCR6
+ lymphoid-tissue-inducer-like ILC3s and T-bet + ILC3s [11] [12] [13] . IL-2 in the small intestine was produced by both subsets of ILC3s, with a significantly higher frequency of T-bet + ILC3s that produce IL-2 (Extended Data Fig. 4e ). Production of IL-2 by ILC3s was confirmed by flow cytometry analyses of the small intestine of Rag1 −/− mice, which revealed that the major population of IL-2 + cells comprises CD127 
j). Unbiased analyses of the large intestine of Rag1
−/− mice indicated that the major population of IL-2 + cells is comprised of innate lymphoid cells (Extended Data Fig. 4k) . Furthermore, the frequency of IL-2 + cells that we observed in the small intestine of Rag2 −/− mice was significantly reduced in Rag2
Il2rg
−/− mice deficient in innate lymphoid cells, or Rag2
−/− mice depleted of innate lymphoid cells with anti-CD90.2 antibody (Fig. 1g) . Collectively, these findings demonstrate that IL-2 is dominantly produced by ILC3s in the healthy small intestine.
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ILC3 development and function can be markedly influenced by the intestinal microbiota [11] [12] [13] . To investigate whether the intestinal microbiota also regulates ILC3-intrinsic IL-2 production, we examined the small intestine of conventionally housed specific-pathogen-free mice, specific-pathogen-free mice exposed to broad-spectrum antibiotics and germ-free mice. Notably, germ-free mice or specific-pathogen-free mice that were exposed to broad-spectrum antibiotics displayed significantly decreased IL-2 production by ILC3s, relative to specific-pathogen-free mice (Fig. 2a) . To determine the signals that directly induce ILC3-intrinsic IL-2 production, we stimulated sort-purified ILC3s from the small intestine with IL-1β, IL-6, IL-23 or the aryl hydrocarbon receptor agonist FICZ, which are all known to directly stimulate ILC3s [11] [12] [13] . Among these, we found that IL-1β selectively induced Il2 transcription and protein production in ILC3s (Fig. 2b, c) . We observed comparable results with stimulation using IL-1α (Fig. 2d) . Furthermore, IL-1β was sufficient to significantly boost IL-2 production in ILC3s from germ-free mice and specific-pathogen-free mice exposed to broad-spectrum antibiotics (Fig. 2e, f) .
Gene-expression analyses of intestinal phagocytes revealed that the majority of IL-1β in the small intestine is produced by macrophages (Fig. 2g) . Consistent with this, macrophages isolated from the small intestine of germ-free mice exhibited significantly reduced IL-1β expression and could be partially restored by mono-colonization with segmented filamentous bacteria (Fig. 2h) , a component of the mouse microbiota that is known to colonize the distal small intestine, induce IL-1β, activate ILC3s and promote expansion of T reg cells [14] [15] [16] . Monocolonization with segmented filamentous bacteria was sufficient to significantly induce ILC3-derived IL-2 production (Fig. 2i) . To explore the sensing modules that are required to promote the IL-1β-ILC3-IL-2 axis, we examined Myd88 −/− mice and observed a significant reduction in expression of IL-1β by macrophages (Fig. 2j) . The intracellular pattern recognition receptor NOD2 has also previously been linked to the processing and secretion of IL-1β 17 . Consistent with this, we observed comparable transcript levels of IL-1β in macrophages that were sorted from the small intestine of Nod2 −/− mice, but ILC3-derived IL-2 was significantly reduced and could be completely restored by stimulation with recombinant IL-1β (Fig. 2j, k) . These data reveal that MYD88-and NOD2-dependent sensing of the intestinal microbiota is essential to promote macrophage production of IL-1β and activate ILC3s to produce IL-2.
To directly investigate whether IL-1R signalling is essential for IL-2 production by ILC3s in vivo, we crossed Ncr1 cre and IL-1R-floxed mice to selectively delete IL-1R in the NKp46 + subset of ILC3s 18, 19 . In comparison to littermate controls, Ncr1 cre
Il1r
f/f mice exhibit reduced IL-2 production by ILC3s, and display a significant decrease of T reg cells in the small intestine (Fig. 3a, b) . To directly investigate the role of ILC3-derived IL-2, we generated mice with a deletion of IL-2 in ILC3s by using Ncr1 cre Il2 f/f mice. This approach resulted in an efficient loss of IL-2 in T-bet + ILC3s in the small intestine, but did not alter the frequency of IL-2 production in CD4 + T cells or dendritic cells (Extended Data Fig. 5a ). We observed minimal production of IL-2 in natural killer cells and group-1 innate lymphoid cells in the small intestine; these populations do not contribute to T reg cell homeostasis, as no changes were observed after depletion with anti-NK1.1 antibody (Extended Data Fig. 5b-d) . By contrast, we observed a significant reduction in the frequency and overall number of T reg cells in the small intestine of Ncr1 cre Il2 f/f mice, compared to littermate controls (Fig. 3c, Extended Data Fig. 6a ). This reduction in T reg cells was associated with a significant increase in the numbers of T helper type 1 (T H 1) cells, whereas T H 17 cells and the proliferation of CD4 + T cells were unchanged (Fig. 3d, Extended Data Fig. 6b-d) . These results were tissue-specific, as no changes in T reg cells were observed in the large Fig. 6e-g ). This was surprising, given that ILC3s can respond to IL-2; however, we observed that T reg cells exhibit higher levels of the high-affinity IL-2R (also known as CD25) and moreefficiently bind IL-2, relative to ILC3s from the small intestine (Extended Data Fig. 6h, i) .
Loss of ILC3-specific IL-1R or IL-2 significantly reduced the frequencies of peripherally induced T reg cells in the small intestine (marked by low staining of neuropilin-1) in addition to significant reductions of both RORγt + and GATA3 + subsets of T reg cells (Extended Data Fig. 7a-d) . ILC3-derived IL-2 did not affect expression of Lag3, Tgfb1, Ctla4 and Ebi3 in T reg cells, but did result in a modest decrease in expression of Il10 (Extended Data Fig. 7e) . Consistent with this, T reg cells from the small intestine of control and Ncr1 cre
Il2
f/f mice exhibited a comparable potential to suppress effector T cell proliferation when ratios were normalized (Extended Data Fig. 7f, g ). Furthermore, previous studies have identified a role for ILC3s in regulating adaptive immunity in the large intestine through granulocyte-macrophage colony-stimulating factor (GM-CSF) and MHCII [20] [21] [22] . However, loss of GM-CSF or ILC3-specific MHCII did not affect T reg cells in the small intestine or IL-2 production by ILC3s, and-similarly-ILC3-derived IL-2 did not affect ILC3 expression of GM-CSF or MHCII 20 (Extended Data Fig. 8) . These data collectively demonstrate that ILC3-derived IL-2 is a newly identified and non-redundant pathway that supports the population size and homeostasis of peripherally induced T reg cells in the small intestine. Peripheral T reg cells in the small intestine are induced by dietary antigens and maintain oral tolerance 
f/f mice, compared to littermate controls (Fig. 3e) . We assessed whether oral tolerance was intact in these mice using a delayed-type hypersensitivity model 24 . In contrast to littermate controls, feeding OVA to Ncr1 cre -Il2 f/f mice did not induce oral tolerance, and did not protect mice from a delayed-type hypersensitivity reaction characterized by ear swelling and higher titres of anti-OVA immunoglobulin G1 (IgG1) in the serum upon OVA challenge in the periphery (Fig. 3f , g, Extended Data Fig. 6j ). These data are consistent with previous literature that describes maintenance and expansion of antigen-specific T reg cells in the lamina propria of the intestine as a critical step in oral tolerance 25 . These data critically demonstrate that NKp46 + ILC3s are an essential and non-redundant source of IL-2 for maintaining T reg cell homeostasis and promoting oral tolerance uniquely in the small intestine.
We next + ILC3s in small-intestinal lamina propria cells of conventional specific-pathogen-free (SPF), antibiotics-treated specific-pathogen-free (ABX) and germ-free (GF) mice (n = 4). b, Quantitative PCR examination of Il2 transcript in sort-purified ILC3s in the presence of various stimuli (n = 6). Il2 expression was normalized to Hprt1, and then further normalized to the medium control within each mouse. c, Flow cytometry plots with graph of frequency of IL-2 + ILC3s from the small-intestinal lamina propria cells of specific-pathogen-free mice after ex vivo culture (n = 4). d, Small-intestinal lamina propria cells from specific-pathogen-free mice were cultured ex vivo for 4 h with or without IL-1α, and examined for IL-2 + ILC3s by flow cytometry (n = 7). e, f, Small-intestinal lamina propria cells from specific-pathogen-free mice treated with antibiotics (e), or germ-free mice (f), were cultured ex vivo with or without IL-1β, and examined for IL-2 in ILC3s by flow cytometry (n = 4). g, Quantitative PCR analysis of Il1b transcript in sort-purified macrophages (CD45 
Rag1
−/− recipient mice exhibited rapid and substantial weight loss, shorter colon length, spontaneous colonic inflammation characterized by increased inflammatory cell infiltration and significantly increased levels of faecal lipocalin-2 (Extended Data Fig. 9a-d) . Notably, we observed significantly decreased numbers of colonic T reg cells, associated with significantly increased numbers of IL-17A 
−/− recipient mice relative to controls, even though both groups exhibited comparable small-intestinal T reg cells (Extended Data Fig. 9e-h ). These findings suggest a model in which ILC3-derived IL-2 can also modulate immunological homeostasis and prevent inflammation throughout the entire gastrointestinal tract in the context of lymphopenia.
Finally, to investigate whether ILC3s support T reg cells in the human intestine, we examined the frequency of these populations in intestinal biopsies from healthy controls and patients with Crohn's disease. As previously reported 26, 27 , we observed significantly reduced frequencies of T reg cells and ILC3s in the small intestine of patients with Crohn's disease relative to healthy controls, and-notably-we also identified a significant positive correlation between the frequencies of these two cell types within the same biopsy (Fig. 4a-c) . To determine whether the impaired responses of T reg cells are associated with reduced ILC3-derived IL-2, we sort-purified ILC3s from resected small intestinal tissues of patients with Crohn's disease and identified significantly reduced levels of IL2 transcript isolated from inflamed versus non-inflamed regions (Fig. 4d) . In addition, IL-2 + ILC3s were significantly reduced in terminal-ileum biopsies from patients with Crohn's disease relative to healthy controls, and no significant change was observed in IL-2
+ T cells (Fig. 4e, f) . These data indicate that-similar to their role in mice-ILC3s support T reg cells within the human small RORγt-PE-eF610 Letter reSeArCH intestine, and suggest that this pathway becomes dysregulated in the context of Crohn's disease.
Collectively, our studies reveal a pathway of immune regulation that uniquely occurs in the healthy small intestine (Extended Data Fig. 10 ). This pathway is continuously required, involves MYD88-and NOD2-dependent microbial sensing by macrophages, production of IL-1β and induction of ILC3-derived IL-2. Subsequently, this pathway supports intestinal T reg cells, immunological homeostasis and oral tolerance. Our findings in mouse models translated into human samples, and indicate that impaired ILC3-derived IL-2 is linked to a reduction of T reg cells and impaired immune regulation within the small intestine of patients with Crohn's disease. Our results will inform ongoing strategies of therapeutically administering low doses of IL-2 to patients with inflammatory bowel disease, or to individuals with lymphopenia, immune deficiencies or who have been treated with chemotoxic agents. ILC3-derived IL-2 does not exhibit functional redundancy or hierarchies with previously known pathways by which ILC3s regulate adaptive immunity in the large intestine. Rather, our data define tissue-specific differences in the mechanisms by which ILC3s orchestrate immune tolerance in the small and large intestines. This is probably driven by substantial differences in microbial burdens, mucus layers, tissue permeability and metabolite access between these two organs [28] [29] [30] . Our data provide insights into the pathways that support T reg cells in the small intestine, and thus add an important complement to the well-known mechanisms that support T reg cells in the large intestine [4] [5] [6] [7] [8] 30 . Finally, our results substantially advance our understanding of the role and regulation of IL-2 throughout the gastrointestinal tract, and identify a previously unappreciated direct communication between ILC3s and T reg cells.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1082-x. cre were provided by E.V., and only heterozygous Ncr1 cre mice were used in this study. All mice were bred and maintained in specific-pathogen-free facilities at Weill Cornell Medicine and littermates were used as controls in all experiments. C57BL/6 germ-free mice were maintained at the gnotobiotic facility at Weill Cornell Medicine. Sex-and age-matched mice between 8 and 14 weeks of age were used for experiments if not otherwise indicated. Sex was not found to influence results of any experiments. No mice were excluded from the analysis unless clearly indicated. All mouse experiments were approved by, and performed in accordance with, the Institutional Animal Care and Use Committee guidelines at Weill Cornell Medicine. In vivo administration of antibodies and antibiotics. Anti-IL-2 monoclonal antibodies (JES6-1A12 and S4B6-1, BioXCell) were administered intraperitoneally every other day at a dose of 300 μg (150 μg JES6-1A12 plus 150 μg S4B6-1) per mouse starting on day 0 and ending on day 14. Anti-CD90.2 monoclonal antibody (30H12, BioXCell) was administered intraperitoneally every 3 days at a dose of 250 μg per mouse starting on day 0 and ending on day 14, as previously described 21 . Anti-NK1.1 monoclonal antibody (PK136, BioXCell) was administered intraperitoneally every 3 days at a dose of 250 μg per mouse starting on day 0 and ending on day 14. A cocktail of antibiotics (0.25 mg/ml of vancomycin, 0.5 mg/ml of ampicillin, neomycin, gentamicin and metronidazole, and 4 mg/ml sucralose) was continuously administered via drinking water for two weeks.
Isolation of cells from the intestinal lamina propria of mice and humans.
Intestines of mice were removed, cleaned from remaining fat tissue and washed in ice-cold PBS (Corning). Peyer's patches on the small intestine were identified and removed. Intestines were opened longitudinally and washed in ice-cold PBS. Afterwards, mucus was gently removed by forceps and intestines were cut into approximately 0.5-cm sections. Dissociation of epithelial cells was performed by incubation on a shaker in HBSS (Sigma Aldrich) containing 5 mM EDTA (Thermo Fisher Scientific), 1 mM DTT (Sigma Aldrich) and 2% FBS twice for 20 min at 37 °C. After each step, samples were vortexed and the epithelial fraction discarded. Afterwards, samples were washed by PBS and enzymatic digestion was performed in RPMI containing 10% FBS and 0.4 U/ml dispase (Thermo Fisher Scientific), 1 mg/ml collagenase III (Worthington) and 20 μg/ml DNase I (Sigma Aldrich) on a shaker for 45 min at 37 °C. Leukocytes were further enriched by a 40/80% Percoll gradient centrifugation (GE Healthcare).
For human samples, de-identified intestinal biopsies from the terminal ileum of paediatric individuals with Crohn's disease or age-matched controls who did not have inflammatory bowel disease were obtained following Institutional-ReviewBoard-approved protocols from either the Children's Hospital of Philadelphia or the JRI IBD Live Cell Bank Consortium at Weill Cornell Medicine. Informed consent was obtained from all subjects. Tissues were processed by first incubating in 1 mM EDTA, 1 mM DTT and 5% FBS (all from Thermo Fisher Scientific) for 30 min at 37 °C with shaking to remove intestinal epithelial cells. Supernatants were then discarded and the remaining tissues were incubated in 0.5 mg/ml collagenase and 20 μg/ml DNase I for 30 min at 37 °C with shaking to obtain the lamina propria fraction. Any remaining tissues were also included following mechanical dissociation and filtering through a 70-μm cell strainer. All cells were then viably cryopreserved at −150 °C in 90% FBS and 10% DMSO for future side-by-side analyses.
Surgical-resection samples from the small intestine of patients with Crohn's disease were obtained through Institutional-Review-Board-approved protocols from the Center for Advanced Digestive Care at Weill Cornell Medicine. Informed consent was obtained from all subjects. Inflamed and non-inflamed regions were isolated by a trained pathologist. Single-cell suspensions from intestinal tissues were obtained by incubating tissues for 30 min at 37 °C with shaking in stripping buffer (1 mM EDTA, 1 mM DTT and 5% FCS) to remove the epithelial layer. Supernatants were then discarded. Tissues were then mechanically dissociated with a sterile scalpel. The lamina propria fraction was obtained by incubating the dissociated tissues for 1 h at 37 °C with shaking in 2 mg/ml collagenase D (Roche), 0.1 mg/ml DNase I (Sigma Aldrich) and 1 mg/ml of trypsin inhibitor (Gibco) digestion solution. Remaining tissues were then filtered through a 70-μm cell strainer. All cells were then viably cryopreserved in 90% FBS and 10% DMSO for side-by-side analysis at a later time point. Following thawing and filtering through a 70-μm cell strainer, cells were stained with antibodies for flow cytometry acquisition. For intracellular transcription factor or cytokine staining, cells were stained for surface markers, followed by fixation and permeabilization according to the manufacturer's protocol (FOXP3 staining buffer set from Thermo Fisher Scientific). For intracellular cytokine staining, cells were first incubated for 4 h in RPMI with 10% FBS, 50 ng/ml phorbol 12-myristate 13-acetate (PMA), 750 ng/ml ionomycin and 10 μg/ml brefeldin A, all obtained from Sigma Aldrich. IL-2 binding capacity was assessed using a biotinylated IL-2 fluorokine assay kit (R&D Systems), following the manufacturer's instructions. All flow cytometry experiments were performed using a Fortessa II flow cytometer and the FACS Diva software (BD Biosciences), and analysed with FlowJo v.10 software (TreeStar) or sort-purified by using FACSAria II cell sorter (BD Biosciences). and incubated in DMEM with high glucose, supplemented with 10% FBS, 10 mM HEPES, 1 mM sodium pyruvate, non-essential amino acids, 80 μM 2-mercaptoethanol, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Gibco) in the presence of recombinant mouse IL-1β (20 ng/ml, Thermo Fisher Scientific), IL-6 (20 ng/ml, Thermo Fisher Scientific), IL-23 (20 ng/ml, Thermo Fisher Scientific) or FICZ (500 nM, Sigma Aldrich) at 37 °C. For quantitative PCR, cells were treated for 4 h. Induction and measurement of delayed-type hypersensitivity responses. Mice were tolerized by gavage with of 50 mg OVA (Grade III, Sigma Aldrich) on 2 consecutive days. One week later, mice were immunized by subcutaneous injection between the shoulder blades of 300 μg OVA (Grade VI, Sigma Aldrich) in 200 μl PBS/Complete Freud's Adjuvant emulsion (Sigma Aldrich). Two weeks after immunization, mice were challenged by subcutaneous injection of 50 μg OVA (grade VI, Sigma Aldrich) in 20 μl PBS into the right ear pinna; 20 μl PBS without OVA were injected into the left ear pinna for control purposes. Ear thickness was measured in a blinded fashion before and 48 h after injection with a digital precision caliper. OVA-specific ear swelling was calculated as (right ear thickness − left ear thickness) at 48 h − (right ear thickness − left ear thickness) at 0 h. Quantitative PCR. Sort-purified cells were lysed in RLT buffer (Qiagen). RNA was extracted via RNeasy mini kits (Qiagen), as per the manufacturer's instructions. Reverse transcription of RNA was performed using Superscript reverse transcription according to the protocol provided by the manufacturer (Thermo Fisher Scientific). Real-time PCR was performed on cDNA using SYBR green chemistry (Applied Biosystems). Reactions were run on a real-time PCR system (ABI 7500; Applied Biosystems). Samples were normalized to Hprt1 or Gapdh, and displayed as a fold change compared to controls. ELISA. For OVA-specific IgG1 quantification, 40 μg/ml OVA (grade VI) was coated on an ELISA plate, mouse serum was diluted from 1:10 4 to 1 :10 6 , and an anti-OVA IgG1 (Cayman Chemical) standard curve ranging from 0.781 ng/ml to 100 ng/ml was applied. OVA-specific IgG1 was detected using an anti-mouse IgG1-HRP antibody (BD Biosciences). For faecal lipocalin-2 detection, faecal samples were collected and weighted for data normalization, then were homogenized in PBS and centrifuged at 12,000 r.p.m. to remove aggregates, and the resulting supernatant was collected. Afterwards, a sandwich ELISA was performed using mouse lipocalin-2/NGAL DuoSet ELISA (R&D Systems), according to the manufacturer's instructions. Regulatory T cell suppression assay. were demultiplexed with Illumina CASAVA (v. 1.8.2) . Adapters were trimmed from reads using FLEXBAR (v.2.4) and reads were aligned to the NCBI GRCm38/mm10 mouse genome using the STAR aligner (v.2.3.0) with default settings. Reads per gene were counted using Rsubread. One sample of the CD4 + T cell group was removed, as its library size was anomalously small compared to those of the other samples. Genes with at least ten counts in each sample were considered for further analysis. Differential expression was assessed using DESeq2 version 1.14.0 with default parameters and with a false discovery rate of 0.1. Statistical analysis. P values of mouse datasets were determined by paired or unpaired two-tailed Student's t-test with a 95% confidence interval. Variance was analysed using F-test. Welch's correction was performed in case of unequal variance. Where appropriate, Mann-Whitney U-test, Wilcoxon matched-pairs test or two-way ANOVA followed by Bonferroni post-tests were performed. All statistical tests were performed with Graph Pad Prism v.6 software. P values of less than 0.05 were considered to be significant. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
RNA sequencing data are available at Gene Expression Omnibus under accession number GSE126580. All datasets generated and/or analysed during the current study are presented in this published article, the accompanying Source Data or Supplementary Information, or are available from the corresponding author upon reasonable request. n/a Confirmed
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested 
Data analysis
Flow Cytometry data analyzed by FlowJo V10, Statistical analysis all conducted using GraphPad Prism V6.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability RNA-seq data will be deposited and made publically available in the Gene Expression Omnibus under accession number GSE126580.
Wild animals
No wild animals included.
Field-collected samples
No field-collected samples included.
Flow Cytometry Plots
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The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
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Methodology
Sample preparation
Sample preparation is described in methods in the "Isolation of cells from the intestinal lamina propria of mice and humans" section.
Instrument
Fortessa II and Aria II (BD Biosciences)
